Other supply arrangements outside the Pharmaceutical Benefits Scheme (PBS)

Page last updated: 06 March 2018

Instructions for PDF forms

The PDF forms on this page may not open correctly in your browser. Please download the form to your computer before editing.

Life Saving Drugs Program (LSDP)

The Australian Government provides fully subsidised access for eligible patients to expensive and life saving medicines for very rare and life-threatening medical conditions through the LSDP.

To apply on behalf of a patient, the treating physician must complete the initial application form, provide copies of all test results as evidence, and submit a clinic letter and email the completed excel spreadsheet.

For ongoing treatment, the treating physician must submit the separate reapplication form along with copies of all test results as evidence of ongoing eligibility and the completed excel spreadsheet to the LSDP by 1 May every year to continue to receive subsidised treatment through the LSDP.

LSDP Funding Criteria and Conditions

Subsidised access through the LSDP is granted in accordance with specified eligibility criteria and subject to certain conditions:
Life Saving Drugs Program Criteria and Conditions.

Before being considered for inclusion, a drug must first be considered by the Pharmaceutical Benefits Advisory Committee (PBAC) and rejected on the basis of cost effectiveness. The Chief Medical Officer (CMO) advises the Minister for Health on drugs proposed to be included on the LSDP.

Medicines currently funded through the LSDP

There are currently thirteen medicines available to eligible patients for the treatment of nine conditions. To view the Guidelines and application forms, visit:
  1. Imiglucerase (Cerezyme®), Velaglucerase (VPRIV®), Taliglucerase (Elelyso®) and Miglustat (Zavesca®) for the treatment of Gaucher disease (Type 1)
  2. Agalsidase alfa (Replagal®) and Agalsidase beta (Fabrazyme®) for the treatment of Fabry disease
  3. Laronidase (Aldurazyme®) for the treatment of Mucopolysaccharidosis Type I (MPS I)
  4. Idursulfase (Elaprase®) for the treatment of Mucopolysaccharidosis Type II (MPS II)
  5. Elosulfase alfa (Vimizim®) for the treatment of Mucopolysaccharidosis Type IVA (MPSIVA)
  6. Galsulfase (Naglazyme®) for the treatment of Mucopolysaccharidosis Type VI (MPS VI)
  7. Alglucosidase alfa (Myozyme®) for the treatment of Infantile-onset, Juvenile Late-onset or Adult Late-onset Pompe disease
  8. Eculizumab (Soliris®) for the treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH)
  9. Nitisinone (Orfadin®) for the treatment of Hereditary Tyrosinaemia Type I (HTI)
For information regarding the management and dispensing of these expensive life saving drugs, please view the Drug Supply Fact Sheet (PDF 384 KB), Drug Supply Fact Sheet (Word 510 KB).

1. Imiglucerase (Cerezyme®), Velaglucerase (VPRIV®), Taliglucerase (Elelyso®) and Miglustat (Zavesca®) for the treatment of Gaucher disease (Type 1)

2. Agalsidase alfa (Replagal®) and Agalsidase beta (Fabrazyme®) for the treatment of Fabry Disease

3. Laronidase (Aldurazyme®) for the treatment of Mucopolysaccharidosis Type I (MPS I)

4. Idursulfase (Elaprase®) for the treatment of Mucopolysaccharidosis Type II (MPS II)

5. Elosulfase alfa (Vimizim®) for the treatment of Mucopolysaccharidosis Type IVA (MPSIVA)

6. Galsulfase (Naglazyme®) for the treatment of Mucopolysaccharidosis Type VI (MPS VI)

7. Alglucosidase alfa (Myozyme®) for the treatment of Infantile-onset, Juvenile Late-onset or Adult Late-onset Pompe Disease

8. Eculizumab (Soliris®) for the treatment of Paroxysmal Nocturnal Haemoglobinuria (PNH)

9. Nitisinone (Orfadin®) for the treatment of Hereditary Tyrosinaemia Type I


Review of the LSDP

On 28 January 2018 the Minister for Health, the Hon Greg Hunt MP, announced the outcomes of the Review of the LSDP and provided the Government response.

These documents are available at Review of the Life Saving Drugs Program (LSDP).

Stakeholders will be consulted during the implementation phase of the reforms. Any questions on the reforms should be directed to the LSDP Team.

Further Information

Life Saving Drugs Program
Phone: (02) 6289 2336
Fax: (02) 6289 8537
Email: LSDP team